In September 2025, MSD (tradename of Merck & Co., Inc., Rahway, NJ, USA) licensed Evaxion’s vaccine candidate EVX-B3 for a cash payment of $7.5 million. Evaxion is eligible for future development, regulatory and sales milestone payments as well as royalties on net sales
EVX-B3 aims to address a serious global medical issue, targeting a pathogen associated with repeated infections, increasing incidence and often serious medical complications, and for which no vaccines are currently available. MSD carries all cost for further development of EVX-B3.